Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/47953
Title: Interpretable multimodal radiopathomics model predicting pathological complete response to neoadjuvant chemoimmunotherapy in esophageal squamous cell carcinoma
Authors: Qi, Baojia
Jiang, Zhaoyu
Shen, Haixia
Li, Jiacheng
Wang , Zhixiang
Fang, Min
Wang, Changchun
Jiang, Youhua
Yuan, Jingping
BERMEJO DELGADO, Inigo 
Dekker, Andre
De Ruysscher, Dirk
Wee, Leonard
Zhang, Wencheng
Ji, Yongling
Zhang, Zhen
Issue Date: 2025
Publisher: BMJ PUBLISHING GROUP
Source: Journal for immunotherapy of cancer, 13 (12) (Art N° e013840)
Abstract: Background Accurate preoperative prediction of pathological complete response (pCR) following neoadjuvant chemoimmunotherapy (nCIT) could help individualize treatment for patients with esophageal squamous cell carcinoma (ESCC). This study aimed to develop and externally validate an interpretable multimodal machine learning framework that integrates CT radiomics and H&E-stained whole-slide images pathomics to predict pCR.Methods In this multicenter, retrospective study, 335 patients with ESCC who received nCIT followed by esophagectomy were enrolled from three institutions. Patients from one center were divided into a training set (181 patients) and an internal test set (115 patients), while data from the other two centers comprised an external test set (39 patients). We developed unimodal radiomics and pathomics models, and two multimodal fusion models-an intermediate fusion model (MIFM) and a late fusion model (MLFM). Model performance was evaluated using the area under the curve (AUC), accuracy, sensitivity, specificity, and F1 score, with exploratory survival stratification by observed and model-predicted pCR status. Interpretability was treated as a design constraint and operationalized at both the feature and model levels.Results The MIFM outperformed unimodal models and the MLFM across all cohorts, achieving AUC/accuracy/sensitivity/specificity/F1 score of 0.97/0.93/0.84/0.96/0.86 (training set), 0.78/0.87/0.62/0.93/0.63 (internal test set), and 0.76/0.77/0.54/0.88/0.61 (external test set). Both observed and predicted pCR status showed exploratory prognostic stratification for overall survival. Feature definitions were mathematically or morphologically explicit, and case-level/cohort-level explanations together with decision-pathway views provided insights into model reasoning. We additionally provide a user-friendly Graphical User Interface to facilitate clinical practice.Conclusions We developed and externally validated an interpretable radiopathomics fusion framework that predicts pCR after nCIT in ESCC using standard-of-care data. This model holds promise as an effective tool for guiding individualized decisions between surveillance and timely surgery.
Notes: Ji, YL; Zhang, Z (corresponding author), Zhejiang Canc Hosp, Hangzhou Inst Med HIM, Chinese Acad Sci, Hangzhou 310022, Zhejiang, Peoples R China.; Zhang, Z (corresponding author), Maastricht Univ, GROW Res Inst Oncol & Reprod, Dept Radiat Oncol Maastro, Maastricht, Netherlands.; Zhang, Z (corresponding author), Tianjin Med Univ Canc Inst & Hosp, Natl Clin Res Ctr Canc, Tianjins Clin Res Ctr Canc, Dept Radiat Oncol,Key Lab Canc Prevent & Therapy, Tianjin 300060, Peoples R China.
chasexun@163.com; 1565247563@qq.com; c39329@163.com;
jiachengli0107@163.com; zhwang93@163.com; fangmin@zjcc.org.cn;
1027738768@qq.com; 1149607024@qq.com; 1173543323@qq.com;
inigo.bermejo@uhasselt.be; andre.dekker@maastro.nl;
dirk.deruysscher@maastro.nl; leonard.wee@maastro.nl; wczhang@tmu.edu.cn;
jiyl@zjcc.org.cn; zhen.zhang@maastro.nl
Keywords: Esophageal Cancer;Pathologic complete response - pCR;Computed tomography;Pathology
Document URI: http://hdl.handle.net/1942/47953
e-ISSN: 2051-1426
DOI: 10.1136/jitc-2025-013840
ISI #: 001643902500001
Rights: Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See https://creativecommons.org/licenses/by-nc/4.0/.
Category: A1
Type: Journal Contribution
Appears in Collections:Research publications

Files in This Item:
File Description SizeFormat 
e013840.full.pdfPublished version5.44 MBAdobe PDFView/Open
Show full item record

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.